ANTIFUNGAL AGENTS

Feigin and Cherry's Textbook of Pediatric Infectious Diseases, Sixth Edition

Volumn , Issue , 2009, Pages 3271-3308

  Groll, Andreas H ^a   Walsh, Thomas J ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952970681     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4044-6.50257-0     Document Type: Chapter

References (533)

1. P. Aanpreung and G. Veerakul (1997) Itraconazole for treatment of oral candidosis in pediatric cancer patients. J. Med. Assoc. Thai. 80 358-362.
2. S.M. Abdel-Rahman, J. Herron, S. Fallon-Friedlander, et al. (2005) Pharmacokinetics of terbinafine in young children treated for tinea capitis. Pediatr. Infect. Dis. J. 24 886-891.
3. S.M. Abdel-Rahman and M.C. Nahata (1977) Oral terbinafine: A new antifungal agent. Ann. Pharmacother. 31 445-456.
4. S.M. Abdel-Rahman, D.A. Powell and M.C. Nahata (1998) Efficacy of itraconazole in children with Trichophyton tonsurans tinea capitis. J. Am. Acad. Dermatol. 38 443-446.
5. C. Aguilar, I. Pujol, J. Sala and J. Guarro (1998) Antifungal susceptibilities of Paecilomyces species. Antimicrob. Agents Chemother. 42 1601-1604.
6. S.R. Ahmad, S.J. Singer and B.G. Leissa (2001) Congestive heart failure associated with itraconazole. Lancet 357 1766-1767.
7. J. Ahonen, K.T. Olkkola and P.J. Neuvonen (1995) Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br. J. Clin. Pharmacol. 40 270-272.
8. R. Ally, D. Schurmann, W. Kreisel, et al. (2001) A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33 1447-1454.
9. M.A. Amantea, R.A. Bowden, A. Forrest, et al. (1995) Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob. Agents Chemother. 39 2042-2047.
10. E. Anaissie, G.P. Bodey, H. Kantarjian, et al. (1991) Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am. J. Med. 91 142-150.
11. E.J. Anaissie, R.O. Darouiche, D. Abi-Said, et al. (1996) Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin. Infect. Dis. 23 964-972.
12. E. Anaissie, A. Gokoslan, R. Hachem and R. Rubin (1992) Azole therapy for trichosporonosis: Clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin. Infect. Dis. 15 781-787.
13. E.J. Anaissie, N.C. Karyotakis, R. Hachem, et al. (1994) Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J. Infect. Dis. 170 384-389.
14. E.J. Anaissie, D.P. Kontoyiannis, C. Huls, et al. (1995) Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J. Infect. Dis. 172 599-602.
15. E.J. Anaissie, S.E. Vartivarian, D. Abi-Said, et al. (1996) Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study. Am. J. Med. 101 170-176.
16. Anaissie, E., White, M., Uzun, O., et al.: Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: A prospective, randomized, multicenter trial. Abstract LM 21. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 1995, pp. 330.
17. D. Andes and M. van Ogtrop (1999) Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43 2116-2120.
18. D. Andes and M. van Ogtrop (2000) In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob. Agents Chemother. 44 938-942.
19. D. Andes, A. Lepak, J. Nett, et al. (2006) In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling. Antimicrob. Agents Chemother. 50 2384-2394.
20. D. Andes, K. Marchillo, R. Conklin, et al. (2004) Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother. 48 137-142.
21. D. Andes, K. Marchillo, T. Stamstad and R. Conklin (2003) In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47 3165-3169.
22. D. Andes, T. Stamsted and R. Conklin (2001) Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob. Agents Chemother. 45 922-926.
23. E.G. Arathoon, E. Gotuzzo, L.M. Noriega, et al. (2002) Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 46 451-457.
24. Arieta, A., Maddison, P., Groll, A. H.: Micafungin in pediatric patients: assessment of safety in clinical trials. Abstracts of the 47 th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC 2007: Abstr. M-1162, p. 441.
25. M. Arning, K.O. Kliche, A.H. Heer-Sonderhoff, et al. (1995) Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38 459-465.
26. M. Arning and R.E. Scharf (1989) Prevention of amphotericin B induced nephrotoxicity by loading with sodium-chloride: A report of 1291 days of treatment with amphotericin B without renal failure. Klin. Wochenschr. 67 1020-1028.
27. Arrieta, A., Queiroz-Telles, F., Berezin, E., et al.: Micafungin vs. liposomal amphotericin B in pediatric patients with invasive candidiasis or candidemia. Abstract O-141. In Abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases. Munich, European Society for Clinical Microbiology and Infectious Diseases, 2007.
28. W.M. Artis, B.M. Odle and H.E. Jones (1981) Griseofulvin-resistant dermatophytosis correlates with in vitro resistance. Arch. Dermatol. 117 16-19.
29. Astellas Pharma GmbH: Mycamine: Summary of product characteristics. Accessed 31-Dec-2008 at http://www.emea.europa.eu/humandocs/PDFs/EPAR/mycamine/H-734-PI-en.pdf.
30. A.J. Atkinson Jr. and J.E. Bennett (1978) Amphotericin B pharmacokinetics in humans. Antimicrob. Agents Chemother. 13 271-276.
31. S.K. Balani, X. Xu, B.H. Arison, et al. (2000) Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab. Dispos. 28 1274-1278.
32. J.E. Baley, R.M. Kliegman and A.A. Fanaroff (1984) Disseminated fungal infections in very low-weight infants: Therapeutic toxicity. Pediatrics 73 153-157.
33. J.E. Baley, C. Meyers, R.M. Kliegman, et al. (1990) Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J. Pediatr. 116 791-797.
34. J.A. Balfour and D. Faulds (1992) Terbinafine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 43 259-284.
35. F. Barchiesi, L.K. Najvar, M.F. Luther, et al. (1996) Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Antimicrob. Agents Chemother. 40 1317-1320.
36. F. Barchiesi, A.M. Schimizzi, L.K. Najvar, et al. (2001) Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 45 1355-1359.
37. F. Barchiesi, E. Spreghini, M. Maracci, et al. (2004) In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob. Agents Chemother. 48 3317-3322.
38. J.A. Barone, B.L. Moskovitz, J. Guarnieri, et al. (1998) Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob. Agents Chemother. 42 1862-1865.
39. K. Bartizal, C.J. Gill, G.K. Abruzzo, et al. (1997) In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41 2326-2332.
40. Barton, E., Zinnes, H., Moe, R. A., and Kulesza, J. S.: Studies on a new solubilized preparation of amphotericin B. In Antibiotics Annual, 1957-1958. New York, Medical Encyclopedia, 1958, pp. 53-57.
41. I. Bekersky, R.M. Fielding, D.E. Dressler, et al. (2002) Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B(AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46 828-833.
42. I. Bekersky, R.M. Fielding, D.E. Dressler, et al. (2002) Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46 834-840.
43. D.K. Benjamin Jr., T. Driscoll, N.L. Seibel, et al. (2006) Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother. 50 632-638.
44. J.E. Bennett (1995) Antifungal agents. G.L. Mandell, J.E. Bennett, R. Dolin (Eds) Principles and Practice of Infectious Diseases 4th ed. New York: Churchill Livingstone 401-410.
45. J.E. Bennett, W.E. Dismukes, M. Haywood, et al. (1979) A comparison of amphotericin B alone and in combination with flucytosine in the treatment of cryptococcal meningitis. N. Engl. J. Med. 301 126-131.
46. J.M. Benson and M.C. Nahata (1989) Pharmacokinetics of amphotericin B in children. Antimicrob. Agents Chemother. 33 1989-1993.
47. J. Berenguer, N.M. Ali, M.C. Allende, et al. (1994) Itraconazole for experimental pulmonary aspergillosis: Comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob. Agents Chemother. 38 1303-1308.
48. J. Berenguer, J.L. Rodriguez-Tudela, C. Richard, et al. (1997) Deep infections caused by Scedosporium prolificans: A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore) 76 256-265.
49. R. Bergner, M. Hoffmann, K.D. Riedel, et al. (2006) Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): Need for a high daily dose of 800 mg. Nephrol. Dial. Transplant. 21 1019-1023.
50. T. Berl, K.D. Wilner, M. Gardner, et al. (1995) Pharmacokinetics of fluconazole in renal failure. J. Am. Soc. Nephrol. 6 242-247.
51. G. Bertini, S. Perugi, C. Dani, et al. (2005) Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J. Pediatr. 147 162-165.
52. H. Bilgen, E. Ozek, V. Korten, et al. (1995) Treatment of systemic neonatal candidiasis with fluconazole. Infection 23 394.
53. E.R. Block and J.E. Bennett (1992) Pharmacological studies with 5-fluorocytosine. Antimicrob. Agents Chemother. 1 476-482.
54. E.R. Block, A.E. Jennings and J.E. Bennet (1973) Experimental therapy of cladosporiosis and sporotrichosis with 5-fluorocytosine. Antimicrob. Agents Chemother. 3 95-98.
55. J.L. Blumer (1999) Pharmacologic basis for the treatment of tinea capitis. Pediatr. Infect. Dis. J. 18 191-199.
56. Blumer, J., Hare, R., Krishna, G., et al.: Efficacy of posaconazole salvage therapy in pediatric subjects with invasive fungal infections. Abstract P-744. In Proceedings of the 15th European Congress for Clinical Microbiology and Infectious Diseases. Munich, European Society for Clinical Microbiology and Infectious Diseases, 2005.
57. A. Bohme, A. Ganser and D. Hoelzer (1995) Aggravation of vincristine-induced neuro-toxicity by itraconazole in the treatment of adult ALL. Ann. Hematol. 71 311-312.
58. A. Bonifaz, A. Saul, V. Paredes-Solis, et al. (2005) Treatment of chromoblastomycosis with terbinafine: Experience with four cases. J. Dermatolog. Treat. 16 47-51.
59. M.A. Boogaerts, J. Maertens, R. Van Der Geest, et al. (2001) Pharmaco-kinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob. Agents Chemother. 45 981-985.
60. M.A. Boogaerts, G.E. Verhoef, P. Zachee, et al. (1989) Antifungal prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels. Mycoses 32(Suppl. 1), 103-108.
61. M. Boogaerts, D.J. Winston, E.J. Bow, et al. (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: A randomized, controlled trial. Itraconazole Neutropenia Study Group. Ann. Intern. Med. 135 412-422.
62. C.M. Botas, I. Kurlat, S.M. Young and A. Sola (1995) Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics 95 883-887.
63. E.I. Boutati and E.J. Anaissie (1997) Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management. Blood 90 999-1008.
64. R. Bowden, P. Chandrasekar, M.H. White, et al. (2002) A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35 359-366.
65. J. Brajtburg, W.G. Powderly, G.S. Kobayashi and G. Medoff (1990) Amphotericin B: Current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34 183-188.
66. K.W. Brammer and P.E. Coates (1994) Pharmacokinetics of fluconazole in pediatric patients. Eur. J. Clin. Microbiol. Infect. Dis. 13 325-329.
67. K.W. Brammer, P.R. Farrow and J.K. Faulkner (1990) Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 12(Suppl. 3), 318-326.
68. A.E. Brouwer, A. Rajanuwong, W. Chierakul, et al. (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: A randomised trial. Lancet 363 1764-1767.
69. H.R. Bruckbauer and H. Hofmann (1997) Systemic antifungal treatment of children with terbinafine. Dermatology 195 134-136.
70. I. Buggia, M. Zecca, E.P. Alessandrino, et al. (1996) Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation: GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res. 16 2083-2088.
71. P.A. Burch, J.E. Karp, W.G. Merz, et al. (1987) Favorable outcome of invasive aspergillosis in patients with acute leukemia. J. Clin. Oncol. 5 1985-1993.
72. D.S. Burgess and R.W. Hastings (2000) A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology. Diagn. Microbiol. Infect. Dis. 38 87-93.
73. D.S. Burgess, R.W. Hastings, K.K. Summers, et al. (2000) Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans. Diagn. Microbiol. Infect. Dis. 36 13-18.
74. K.M. Butler, M.A. Rench and C.J. Baker (1990) Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr. Infect. Dis. J. 9 51-56.
75. W.T. Butler, J.E. Bennett, D.W. Alling, et al. (1964) Nephrotoxicity of amphotericin B: Early and late effects in 81 patients. Ann. Intern. Med. 62 175-187.
76. H. Caceres-Rios, M. Rueda, R. Ballona and B. Bustamante (2000) Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. J. Am. Acad. Dermatol. 42 80-84.
77. D. Caillot, H. Bassaris, A. McGeer, et al. (2001) Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin. Infect. Dis. 33 e83-e90.
78. Cancidas (caspofungin acetate) for Injection Label Information (February 2005). Washington, D.C., U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
79. R.Y. Cartwright (1978) Use of antibiotics: Antifungals. Br. Med. J. 2 101-111.
80. I. Castberg, J. Helle and T.O. Aamo (2005) Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther. Drug Monit. 27 680-682.
81. A. Catanzaro, J.N. Galgiani, B.E. Levine, et al. (1995) Fluconazole in the treatment of chronic pulmonary and non-meningeal disseminated coccidioidomycosis. Am. J. Med. 98 249-256.
82. P.H. Chandrasekar (2005) Antifungal resistance in Aspergillus. Med. Mycol. 43(Suppl. 1), S295-S298.
83. K.M. Chan-Tack, C.L. Thio, N.S. Miller, et al. (1999) Paecilomyces lilacinus fungemia in an adult bone marrow transplant recipient. Med. Mycol. 37 57-60.
84. S.W. Chapman, R.W. Bradsher Jr., G.D. Campbell Jr., et al. (2000) Practice guidelines for the management of patients with blastomycosis: Infectious Diseases Society of America. Clin. Infect. Dis. 30 679-683.
85. S.W. Chapman, P. Pappas, C. Kauffmann, et al. (2004) Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses 47 62-68.
86. C.C. Chiou, A.H. Groll and T.J. Walsh (2000) New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 5 120-135.
87. C.C. Chiou, T.J. Walsh and A.H. Groll (2007) Clinical pharmacology of antifungal agents in pediatric patients. Expert Opin. Pharmacother. 8 2465-2489.
88. K.J. Christiansen, E.M. Bernard, J.W.M. Gold and D. Armstrong (1985) Distribution and activity of amphotericin B in humans. J. Infect. Dis. 152 1037-1043.
89. C.J. Clancy and M.H. Nguyen (1998) In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 17 573-575.
90. K.V. Clemons and D.A. Stevens (1998) Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob. Agents Chemother. 42 899-902.
91. J.A. Como and W.E. Dismukes (1994) Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330 263-272.
92. C. Contini, D. Colombo, R. Cultrera, et al. (1996) Employment of terbinafine against Pneumocystis carinii infection in rat models. Br. J. Dermatol. 134(Suppl. 46), 30-32.
93. C. Contini, M. Manganaro, R. Romani, et al. (1994) Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia. J. Antimicrob. Chemother. 34 727-735.
94. O.A. Cornely, J. Maertens, M. Bresnik and R. Herbrecht (2005) Liposomal amphotericin B as initial therapy for invasive filamentous fungal infections: A randomized, prospective trial of a high loading regimen versus a standard dosing (AmBiLOAD Trial). Abstract. Blood 106 900.
95. O.A. Cornely, J. Maertens, D.J. Winston, et al. (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356 348-359.
96. Courtney, R.: Pharmacokinetics of posaconazole in patients with hepatic insufficiency. In Abstracts of the Annual Meeting of the American Academy for Pharmacological Sciences (AAPS). Abstract 3495. Washington, D.C., American Academy for Pharmacological Sciences, 2000.
97. R. Courtney, S. Pai, M. Laughlin, et al. (2003) Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47 2788-2795.
98. Courtney, R., Sansone, A., and Devlin, D.: P-glycoprotein expression and genotype: Exploratory analysis of posaconazole in healthy volunteers. Abstract A-40. In Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2004.
99. R. Courtney, A. Sansone, W. Smith, et al. (2005) Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol. 45 185-192.
100. P.C. Craven, T.M. Ludden, D.J. Drutz, et al. (1979) Excretion pathways of amphotericin B. J. Infect. Dis. 140 329-341.
101. T.K. Daneshmend and D.W. Warnock (1983) Clinical pharmacokinetics of systemic antifungal drugs. Clin. Pharmacokinet. 8 17-42.
102. K. De Beule (1996) Itraconazole: Pharmacology, clinical experience and future development. Int. J. Antimicrob. Agents 6 175-181.
103. K. De Beule and J. Van Gestel (2001) Pharmacology of itraconazole. Drugs 61(Suppl. 1), 27-37.
104. N. de Wet, A.J. Bester, J.J. Viljoen, et al. (2005) A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment. Pharmacol. Ther. 21 899-907.
105. N. de Wet, A. Llanos-Cuentas, J. Suleiman, et al. (2004) A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. 39 842-849.
106. M. Debono and R.S. Gordee (1994) Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol. 48 471-497.
107. D.W. Denning (2003) Echinocandin antifungal drugs. Lancet 362 1142-1151.
108. D.W. Denning and D.A. Stevens (1992) Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases. Rev. Infect. Dis. 12 1147-1201.
109. D.W. Denning, K.A. Marr, W.M. Lau, et al. (2006) Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect. 53 337-349.
110. D.W. Denning, S.A. Radford, K.L. Oakley, et al. (1997) Correlation between in vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40 401-414.
111. D.W. Denning, P. Ribaud, N. Milpied, et al. (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34 563-571.
112. D.W. Denning, R.M. Tucker, L.H. Hanson and D.A. Stevens (1989) Treatment of invasive aspergillosis with itraconazole. Am. J. Med. 86 791-800.
113. L. de Repentigny, J. Ratelle, J.M. Leclerc, et al. (1998) Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob. Agents Chemother. 42 404-408.
114. G. Di Bonaventura, I. Spedicato, C. Picciani, et al. (2004) In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob. Agents Chemother. 48 4453-4456.
115. M. Diaz, R. Negroni, F. Montero-Gei, et al. (1992) A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host: Pan-American Study Group. Clin. Infect. Dis. 14(Suppl. 1), 68-76.
116. D.J. Diekema, B. Petroelje, S.A. Messer, et al. (2005) Activities of available and investigational antifungal agents against rhodotorula species. J. Clin. Microbiol. 43 476-478.
117. W.E. Dismukes, R.W. Bradsher, G.C. Cloud, et al. (1992) Itraconazole therapy for blastomycosis and histoplasmosis. Am. J. Med. 93 489-497.
118. D.M. Dixon and A. Polak (1987) In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy 33 129-140.
119. A.R. Dodgson, K.J. Dodgson, C. Pujol, et al. (2004) Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob. Agents Chemother. 48 2223-2227.
120. C.M. Douglas (2006) Understanding the microbiology of the Aspergillus cell wall and the efficacy of caspofungin. Med. Mycol. 44(Suppl), 95-99.
121. R.H. Drew and J.R. Perfect (1998) Flucytosine. V.L. Yu, T.C. Merigan, S. Barriere (Eds) Antimicrobial Chemotherapy and Vaccines Baltimore: Williams & Wilkins 1170-1184.
122. R.H. Drew, E. Dodds Ashley, D.K. Benjamin Jr., et al. (2004) Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 77 232-237.
123. M. Driessen, J.B. Ellis, P.A. Cooper, et al. (1996) Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: A prospective randomized trial. Pediatr. Infect. Dis. J. 15 1107-1112.
124. M. Driessen, J.B. Ellis, F. Muwazi and F.P. De Villiers (1997) The treatment of systemic candidiasis in neonates with oral fluconazole. Ann. Trop. Paediatr. 7 263-271.
125. D.J. Drutz, A. Spickard, D.E. Rogers and M.G. Koenig (1968) Treatment of disseminated mycotic infections: A new approach to amphotericin B therapy. Am. J. Med. 45 405-418.
126. B. Dupont, J. de Waele, R. Betts, et al. (2007) Micafungin vs. caspofungin in patients with invasive candidiasis or candidemia: A phase III, randomized double-blind parallel group, non-inferiority trial. Abstract O-140. Abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases Munich: European Society for Clinical Microbiology and Infectious Diseases
127. B.E. Elewski (1996) Cutaneous mycoses in children. Br. J. Dermatol. 134(Suppl. 46), 7-11.
128. EORTC International Antimicrobial Therapy Cooperative Group (1986) Empiric antifungal therapy in febrile granulocytopenic patients. Am. J. Med. 86 668-672.
129. W.L. Epstein, V.P. Shah and S. Riegelman (1992) Griseofulvin levels in stratum corneum. Study after oral administration in man. Arch. Dermatol. 106 344-348.
130. Eraxis (anidulafungin) for Injection Label Information (January 2007). Washington, D.C., U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
131. E.J. Ernst, M.E. Klepser, M.E. Ernst, et al. (1999) In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis. 33 75-80.
132. E.J. Ernst, M.E. Klepser and M.A. Pfaller (2000) Postantifungal effects of echinocandin, azole, and polyene antifungal agents Candida albicans and Cryptococcus neoformans. Antimicrob. Agents. Chemother. 44 1108-1111.
133. M.E. Ernst, M.E. Klepser, E.J. Wolfe and M.A. Pfaller (1996) Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Diagn. Microbiol. Infect. Dis. 26 125-131.
134. A. Espinel-Ingroff (1998) Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36 2950-2956.
135. C. Fasano, J. O'Keeffe and D. Gibbs (1994) Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur. J. Clin. Microbiol. Infect. Dis. 13 351-354.
136. B. Fernandez-Torres, A.J. Carrillo, E. Martin, et al. (2001) In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob. Agents Chemother. 45 2524-2528.
137. D. Fleece, J.P. Gaughan and S.C. Aronoff (2004) Griseofulvin versus terbinafine in the treatment of tinea capitis: A meta-analysis of randomized, clinical trials. Pediatrics 114 1312-1315.
138. P. Flynn, C.K. Cunningham, T. Kerkering, et al. (1995) Oropharyngeal candidiasis in immunocompromised children: A randomized, multicenter study of orally administered fluconazole suspension versus nystatin. J. Pediatr. 127 322-328.
139. Flynn, P., Seibel, N., Arrieta, A., et al.: Treatment of invasive aspergillosis in pediatric patients with micafungin alone or in combination with other systemic antifungal agents. Abstract M-891. In Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2006, pp. 407.
140. A. Foot, P. Veys and B. Gibson (1999) Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 24 1089-1093.
141. Fothergill, A. W., Leitner, I., Meingassner, J. G., et al.: Combination antifungal susceptibility testing of terbinafine and the triazoles fluconazole and itraconazole. Abstract E-53. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 1996, pp. 91.
142. P. Francis and T.J. Walsh (1992) Evolving role of flucytosine in immunocompromised patients: New insights into safety, pharmacokinetics, and antifungal therapy. Clin. Infect. Dis. 15 1003-1018.
143. J.A. Franklin, J. McCormick and P.M. Flynn (2003) Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr. Infect. Dis. J. 22 747-749.
144. S.F. Friedlander (1999) The evolving role of itraconazole, fluconazole and terbinafine in the treatment of tinea capitis. Pediatr. Infect. Dis. J. 18 205-210.
145. S.F. Friedlander and S. Suarez (1998) Pediatric antifungal therapy. Dermatol. Clin. 16 527-537.
146. S.F. Friedlander, R. Aly, B. Krafchik, et al. (2002) Terbinafine in the treatment of Trichophyton tinea capitis: A randomized, double-blind, parallel-group, duration-finding study. Pediatrics 109 602-607.
147. L.C. Fuller, C.H. Smith, R. Cerio, et al. (2001) A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis. Br. J. Dermatol. 144 321-327.
148. J.C. Fung-Tomc, E. Huczko, B. Minassian and D.P. Bonner (1998) In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. 42 313-318.
149. J.N. Galgiani, N.M. Ampel, A. Catanzaro, et al. (2000) Practice guideline for the treatment of coccidioidomycosis: Infectious Diseases Society of America. Clin. Infect. Dis. 30 658-661.
150. J.N. Galgiani, A. Catanzaro, G.A. Cloud, et al. (1993) Fluconazole therapy for coccidioidal meningitis. Ann. Intern. Med. 119 28-35.
151. J.N. Galgiani, A. Catanzaro, G.A. Cloud, et al. (2000) Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: A randomized, double-blind trial. Mycoses Study Group. Ann. Intern. Med. 133 676-686.
152. M.T. Garcia, M.T. Llorente, J.E. Lima, et al. (1999) Activity of voriconazole: Post-antifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. Scand. J. Infect. Dis. 31 501-504.
153. G. Garcia-Effron, A. Gomez-Lopez, E. Mellado, et al. (2004) In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J. Antimicrob. Chemother. 53 1086-1089.
154. R.E. Gardiner, P. Souteropoulos, S. Park and D.S. Perlin (2005) Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med. Mycol. 43(Suppl. 1), S299-S305.
155. A. Gehrt, J. Peter, P.A. Pizzo and T.J. Walsh (1995) Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J. Clin. Microbiol. 33 1302-1307.
156. J.C. Gentles (1958) Experimental ringworm in guinea pigs: Oral treatment with griseofulvin. Nature 182 476-477.
157. N.H. Georgopapadakou (2001) Update on antifungals targeted to the cell wall: Focus on beta-1,3-glucan synthase inhibitors. Expert Opin. Investig. Drugs 10 269-280.
158. A. Glasmacher, C. Hahn, E. Molitor, et al. (1999) Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 42 591-600.
159. Glasmacher, A., Hahn, C., Molitor, E., et al.: Definition of itraconazole target concentration for antifungal prophylaxis. Abstract 700. In Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2000, pp. 363.
160. A. Glasmacher, A. Prentice, M. Gorschluter, et al. (2003) Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J. Clin. Oncol. 21 4615-4626.
161. C. Glick, G.R. Graves and S. Feldman (1993) Neonatal fungemia and amphotericin B. South. Med. J. 86 1368-1371.
162. K.L. Goa and L.B. Barradell (1995) Fluconazole: An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50 658-690.
163. Gold, W., Stout, H. A., Pagona, I. F., and Donovick, R.: Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. In Antibiotics Annual, 1955-1956. New York, Medical Encyclopedia, 1955, pp. 579-586.
164. M. Goldman, G.A. Cloud, M. Smedema, et al. (2000) Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? Antimicrob. Agents Chemother. 44 1585-1587.
165. R.D. Goldman and G. Koren (2004) Amphotericin B nephrotoxicity in children. J. Pediatr. Hematol. Oncol. 26 421-426.
166. A. Gomez-Lopez, M. Cuenca-Estrella, E. Mellado, et al. (2003) In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota. Diagn. Microbiol. Infect. Dis. 45 199-202.
167. J.L. Goodman, D.J. Winston, R.A. Greenfield, et al. (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326 845-851.
168. J.H. Googe and J.N. Walterspiel (1988) Arrhythmia caused by amphotericin B in a neonate. Pediatr. Infect. Dis. J. 7 73.
169. S.M. Grant and S.P. Clissold (1989) Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37 310-344.
170. S.M. Grant and S.P. Clissold (1990) Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39 877-916.
171. J.R. Graybill, D.A. Stevens, J.N. Galgiani, et al. (1990) Itraconazole treatment of coccidioidomycosis. Am. J. Med. 89 282-290.
172. A.H. Groll and T.J. Walsh (2001) Caspofungin: Pharmacology, safety, and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs 10 1545-1558.
173. A.H. Groll and T.J. Walsh (2001) Uncommon opportunistic fungi: New nosocomial threats. Clin. Microbiol. Infect. 7(Suppl. 2), 8-24.
174. A.H. Groll and T.J. Walsh (2005) Posaconazole: Clinical pharmacology and potential for management of fungal infections. Expert Rev. Anti. Infect. Ther. 3 467-487.
175. A.H. Groll, A. Attarbaschi, F.R. Schuster, et al. (2006) Treatment with caspofungin in immunocompromised paediatric patients: A multicentre survey. J. Antimicrob. Chemother. 57 527-535.
176. A.H. Groll, C.C. Chiou and T.J. Walsh (2001) Antifungal drugs: Drug interactions with antifungal azole derivatives. J.K. Aronson, C.J. van Boxtel (Eds) Side Effects of Drugs, Annual 24 Amsterdam: Elsevier Science 314-329.
177. A.H. Groll, J.C. Gea-Banacloche, A. Glasmacher, et al. (2003) Clinical pharmacology of antifungal compounds. Infect. Dis. Clin. North Am. 17 159-191.
178. A.H. Groll, N. Giri, V. Petraitis, et al. (2000) Comparative central nervous system distribution and antifungal activity of lipid formulations of amphotericin B in rabbits. J. Infect. Dis. 182 274-282.
179. A.H. Groll, G. Just-Nuebling, M. Kurz, et al. (1997) Fluconazole versus nystatin in the prevention of Candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. J. Antimicrob. Chemother. 40 855-862.
180. A.H. Groll, H. Kolve, T.J. Walsh (2005) Azoles. V.L. Yu, G. Edwards, P.S. Mckinnon, et al., (Eds) 2nd ed. Antimicrobial Chemotherapy and Vaccines 2 Pittsburgh, PA: ESun Technologies 609-636.
181. A.H. Groll, D. Mickiene, M. McEvoy, et al. (2002) Safety, pharmacokinetics and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 46 2554-2563.
182. Groll, A. H., Mickiene, D., Petraitiene, R., et al.: Pharmacokinetics and pharmacodynamics of posaconazole (SCH 56592) in a neutropenic animal model of invasive pulmonary aspergillosis. Abstract 1675. In Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2000, pp. 385.
183. A.H. Groll, D. Mickiene, R. Petraitiene, et al. (2001) Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother. 45 2845-2855.
184. A.H. Groll, F.M. Muller, S.C. Piscitelli and T.J. Walsh (1998) Lipid formulations of amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer. Klin. Padiatr. 210 264-273.
185. A. Groll, U. Nowak-Goettl, A. Wildfeuer, et al. (1992) Fluconazole treatment of oropharyngeal candidosis in pediatric cancer patients with severe mucositis following antineoplastic chemotherapy. Mycoses 35(Suppl.), 35-40.
186. A.H. Groll, S.C. Piscitelli and T.J. Walsh (1998) Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44 343-500.
187. A.H. Groll, S.C. Piscitelli and T.J. Walsh (2001) Antifungal pharmacodynamics: Concentration-effect relationships in vitro and in vivo. Pharmacotherapy 21(Suppl. 8), 133-148.
188. A.H. Groll, J. Ritter and F.M.C. Mueller (2001) Prevention of fungal infections in children and adolescents with cancer. Klin. Paediatr. 213(Suppl. 1), A50-A68.
189. A.H. Groll, T. Stergiopoulou, E. Roilides and T.J. Walsh (2005) Micafungin: Pharmacology, experimental therapeutics and clinical applications. Expert Opin. Investig. Drugs 14 489-509.
190. P.O. Gubbins, S.A. McConnell and S.R. Penzak (2001) Antifungal agents. S.C. Piscitelli, K.A. Rodvold (Eds) Drug Interactions in Infectious Diseases Totowa, NJ: Humana Press 185-217.
191. K. Gull and A.P. Trinci (1973) Griseofulvin inhibits fungal mitosis. Nature 244 292-294.
192. A.K. Gupta and G.S. Ross (1998) Interaction between terbinafine and warfarin. Dermatology 196 266-267.
193. A.K. Gupta, S. Nolting, Y. de Prost, et al. (1999) The use of itraconazole to treat cutaneous fungal infections in children. Dermatology 199 248-252.
194. A.K. Gupta, D.N. Sauder and N.H. Shear (1994) Antifungal agents: An overview. J. Am. Acad. Dermatol. 30 677-698. 911-933
195. R.J. Hamill, C.J. Thomas and W.E. Dismukes (1996) Fluconazole therapy for histoplasmosis: The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis. 23 996-1001.
196. J.D. Hamilton and D.M. Elliott (1975) Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice. J. Infect. Dis. 131 129-137.
197. T.C. Hardin, J.R. Graybill, R. Fetchick, et al. (1988) Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob. Agents Chemother. 32 1310-1313.
198. B.E. Harris, B.W. Manning and T.W. Federle (1986) Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob. Agents Chemother. 29 44-48.
199. C.M. Healy, C.J. Baker, E. Zaccaria and J.R. Campbell (2005) Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J. Pediatr. 147 166-171.
200. M.F. Hebert, H.E. Smith, T.C. Marbury, et al. (2005) Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol. 45 1145-1152.
201. R.F. Hector (1993) Compounds active against cell walls of medically important fungi. Clin. Microbiol. Rev. 6 1-21.
202. P. Hegener, P.F. Troke, G. Fakenheuer, et al. (1998) Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 12 2227-2228.
203. H.T. Heidemann, J.F. Gerkens, W.A. Spickard, et al. (1983) Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am. J. Med. 75 476-481.
204. R. Herbrecht (1997) Safety of amphotericin B colloidal dispersion. Eur. J. Clin. Microbiol. Infect. Dis. 16 74-80.
205. R. Herbrecht, D.W. Denning, T.F. Patterson, et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347 408-415.
206. G.P. Heresi, D.R. Gerstmann, M.D. Reed, et al. (2006) The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr. Infect. Dis. J. 25 1110-1115.
207. T. Hernandez-Sempelayo (1994) Fluconazole vs. ketoconazole in the treatment of oropharyngeal candidiasis in HIV-infected children. Eur. J. Clin. Microbiol. Infect. Dis. 13 340-344.
208. J. Heykants, M. Michiels, W. Meuldermans, et al. (1987) The pharmaco-kinetics of itraconazole in animals and man: An overview. R.A. Fromtling (Eds) Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents Barcelona: J. R. Prous 223-249.
209. J.W. Hiemenz and T.J. Walsh (1996) Lipid formulations of amphotericin B: Recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2), 133-144.
210. T. Hilliard, S. Edwards, R. Buchdahl, et al. (2005) Voriconazole therapy in children with cystic fibrosis. J. Cyst. Fibros. 4 215-220.
211. D.J. Hoban, G.G. Zhanel and J.A. Karlowsky (1999) In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob. Agents Chemother. 43 1463-1464.
212. H.L. Hoffman, E.J. Ernst and M.E. Klepser (2000) Novel triazole antifungal agents. Expert Opin. Investig. Drugs 9 593-605.
213. Y. Hong, P.J. Shaw, C.E. Nath, et al. (2006) Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob. Agents Chemother. 50 935-942.
214. P.K. Honig, D.C. Wortham, R. Hull, et al. (1993) Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J. Clin. Pharmacol. 33 1201-1206.
215. W.W. Hope, P.A. Warn, A. Sharp, et al. (2006) Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrob. Agents Chemother. 50 3680-3688.
216. J.E. Hoppe (1997) Treatment of oropharyngeal candidiasis and candidal diaper dermatitis in neonates and infants: Review and reappraisal. Pediatr. Infect. Dis. J. 16 885-894.
217. R. Horn, B. Wong, T.E. Kiehn and D. Armstrong (1985) Fungemia in a cancer hospital: Changing frequency, earlier onset, and results of therapy. Rev. Infect. Dis. 7 646-655.
218. C.R. Horsburgh Jr. and C.H. Kirkpatrick (1983) Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: Experience with twenty-one patients. Am. J. Med. 74 23-29.
219. R.M. Howard and I.J. Frieden (1999) Dermatophyte infections in children. Adv. Pediatr. Infect. Dis. 14 73-107.
220. P.R. Hull and H.F. Vismer (1992) Treatment of cutaneous sporotrichosis with terbinafine. J. Dermatol. 126(Suppl. 39), 51-55.
221. H. Humbert, M.D. Cabiac, J. Denouel and S. Kirkesseli (1995) Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, following a single oral dose in healthy subjects. Biopharm. Drug Dispos. 16 685-694.
222. H. Humbert, J. Denouel, M.D. Cabiac, et al. (1998) Pharmacokinetics of terbinafine and five known metabolites in children, after oral administration. Biopharm. Drug Dispos. 19 417-423.
223. M. Huttova, I. Hartmanova, K. Kralinsky, et al. (1998) Candida fungemia in neonates treated with fluconazole: Report of forty cases, including eight with meningitis. Pediatr. Infect. Dis. J. 17 1012-1015.
224. T.H. Ittel, U.F. Legler, A. Polak, et al. (1987) 5-Fluorocytosine kinetics in patients with acute renal failure undergoing continuous hemofiltration. Chemotherapy 33 77-84.
225. P.C. Iwen, M.E. Rupp, A.N. Langnas, et al. (1998) Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin. Infect. Dis. 26 1092-1097.
226. Jafri, H., Zaoutis, T., Keller, N., et al.: Prospective, multicenter study of caspofungin for treatment of documented fungal infections in pediatric patients. Abstract G-873. In Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2006, p.272.
227. F.A. Jagdis, P.D. Hoeprich, R.M. Lawrence and C.P. Schaffner (1977) Comparative pharmacology of amphotericin B and amphotericin B methyl ester in the non-human primate, Macaca mulatta. Antimicrob. Agents Chemother. 12 582-590.
228. I. Jarque, S. Saavedra, G. Martin, et al. (2000) Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole. Haematologica 85 441-443.
229. C.J. Jessup, N.S. Ryder and M.A. Ghannoum (2000) An evaluation of the in vitro activity of terbinafine. Med. Mycol. 38 155-159.
230. E.M. Johnson, A. Szekely and D.W. Warnock (1998) In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J. Antimicrob. Chemother. 42 741-745.
231. L.B. Johnson and C.A. Kauffman (2003) Voriconazole: A new triazole antifungal agent. Clin. Infect. Dis. 36 630-637.
232. M.D. Johnson, R.H. Drew and J.R. Perfect (1998) Chest discomfort associated with liposomal amphotericin B: Report of three cases and review of the literature. Pharmacotherapy 18 1053-1061.
233. T.C. Jones (1995) Overview of the use of terbinafine (Lamisil) in children. Br. J. Dermatol. 132 683-689.
234. A. Juster-Reicher, O. Flidel-Rimon, M. Amitay, et al. (2003) High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J. Clin. Microbiol. Infect Dis. 22 603-607.
235. A. Juster-Reicher, E. Leibovitz, N. Linder, et al. (2001) Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 28 223-226.
236. V.L. Kan and J.E. Bennett (1988) Efficacies of four antifungal agents in experimental murine sporotrichosis. Antimicrob. Agents Chemother. 32 1619-1623.
237. J.A. Karlowsky, D.J. Hoban, G.G. Zhanel and B.P. Goldstein (2006) In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int. J. Antimicrob. Agents. 27 174-177.
238. J.E. Karp, P.A. Burch and W.G. Merz (1988) An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am. J. Med. 85 203-206.
239. D. Kaufman, R. Boyle, K.C. Hazen, et al. (2001) Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med. 345 1660-1666.
240. D. Kaufman, R. Boyle, K.C. Hazen, et al. (2005) Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J. Pediatr. 147 172-179.
241. C.A. Kauffman, S.F. Bradley, S.C. Ross and D.R. Weber (1991) Hepatosplenic candidiasis: Successful treatment with fluconazole. Am. J. Med. 91 137-141.
242. C.A. Kauffman, R. Hajjeh and S.W. Chapman (2000) Practice guidelines for the management of patients with sporotrichosis: For the Mycoses Study Group. Infectious Diseases Society of America. Clin. Infect. Dis. 30 684-687.
243. C.A. Kauffman, P.G. Pappas, D.S. McKinsey, et al. (1996) Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin. Infect. Dis. 22 46-50.
244. A.R. Kingo, J.A. Smyth and D. Waisman (1997) Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Pediatr. Infect. Dis. J. 16 1002-1003.
245. W.R. Kirkpatrick, A.C. Vallor, R.K. McAtee, et al. (2005) Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis. Antimicrob. Agents Chemother. 49 4751-4753.
246. M.E. Klepser, D. Malone, R.E. Lewis, et al. (2000) Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob. Agents Chemother. 44 1917-1920.
247. M.E. Klepser, E.J. Wolfe, R.N. Jones, et al. (1997) Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41 1392-1395.
248. M.E. Klepser, E.J. Wolfe and M.A. Pfaller (1998) Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J. Antimicrob. Chemother. 41 397-401.
249. G. Kofla and M. Ruhnke (2005) Voriconazole: Review of a broad spectrum triazole antifungal agent. Expert Opin. Pharmacother. 6 1215-1229.
250. L.M. Kohler, P.C. Monteiro, R.C. Hahn and J.S. Hamdan (2004) In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine. J. Clin. Microbiol. 42 4319-4320.
251. H. Kolve, T. Lehrnbecher, K. Ehlert, et al. (2004) Safety, tolerance and plasma concentrations of voriconazole in immunocompromised pediatric patients. Clin. Microbiol. Infect. 10(Suppl. 3), 40-41.
252. H. Kolve, J. Ritter, H. Juergens and A.H. Groll (2005) Safety, tolerance and outcome of treatment with liposomal amphotericin B in pediatric cancer/HSCT patients. Bone Marrow Transplant 35(Suppl. 2), S264-S265.
253. H. Konishi, K. Morita and A. Yamaji (1994) Effect of fluconazole on theophylline disposition in humans. Eur. J. Clin. Pharmacol. 46 309-312.
254. D.P. Kontoyiannis, B.T. Reddy, H. Hanna, et al. (2002) Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect. Control Hosp. Epidemiol. 23 542-545.
255. G. Koren, A. Lau, J. Klein, et al. (1988) Pharmacokinetics and adverse effects of amphotericin B in infants and children. J. Pediatr. 113 559-563.
256. J.M. Kovarik, S. Kirkesseli, H. Humbert, et al. (1992) Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br. J. Dermatol. 126(Suppl. 39), 8-13.
257. J.M. Kovarik, E.A. Mueller, H. Zehender, et al. (1995) Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob. Agents Chemother. 39 2738-2741.
258. B. Krafchik and J. Pelletier (1998) An open study of tinea capitis in 50 children treated with a 2-week course of oral terbinafine. J. Am. Acad. Dermatol. 41 60-63.
259. M.R. Kramer, S.E. Marshall, D.W. Denning, et al. (1990) Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann. Intern. Med. 113 327-329.
260. D.S. Krause, J. Reinhardt, J.A. Vazquez, et al. (2004) Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia: Anidulafungin Invasive Candidiasis Study Group. Antimicrob. Agents Chemother. 48 2021-2024.
261. D.S. Krause, A.E. Simjee, C. van Rensburg, et al. (2004) A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39 770-775.
262. P. Krieter, B. Flannery, T. Musick, et al. (2004) Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob. Agents Chemother. 48 3543-3551.
263. G. Krishna, A. Sansone-Parsons, M. Martinho, et al. (2007) Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob. Agents Chemother. 51 812-818.
264. I. Krzeska, R.A. Yeates and G. Pfaff (1993) Single dose intravenous pharmacokinetics of fluconazole in infants. Drugs Exp. Clin. Res. 19 267-271.
265. B.J. Kullberg, J.D. Sobel, M. Ruhnke, et al. (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial. Lancet 366 1435-1442.
266. M.B. Kurtz and C.M. Douglas (1997) Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. 35 79-86.
267. M.B. Kurtz, I.B. Heath, J. Marrinan, et al. (1994) Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta- d-glucan synthase. Antimicrob. Agents Chemother. 38 1480-1489.
268. D. Lansdorp, H.P. Bressers, J.A. Dekens-Konter and R.H. Meyboom (1999) Potentiation of acenocoumarol during vaginal administration of miconazole. Br. J. Clin. Pharmacol. 47 225-226.
269. R.A. Larsen, S.A. Bozette, B.E. Jones, et al. (1994) Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 19 741-745.
270. A.H. Lau and N.O. Kronfol (1995) Elimination of flucytosine by continuous hemofiltration. Am. J. Nephrol. 15 327-331.
271. A.P.M. Lavrijsen, K.J. Balmus, W.M. Nugteren-Huyning, et al. (1992) Hepatic injury associated with itraconazole. Lancet 340 251-252.
272. R.M. Lawrence, P.D. Hoeprich, F.A. Jagdis, et al. (1980) Distribution of doubly radiolabelled amphotericin B methyl ester and amphotericin B in the non-human primate, Macaca mulatta. J. Antimicrob. Chemother. 6 241-249.
273. J.D. Lazar and K.D. Wilner (1990) Drug interactions with fluconazole. Rev. Infect. Dis. 12(Suppl. 3), 327-333.
274. J.W. Lee, N.L. Seibel, M. Amantea, et al. (1992) Safety, tolerance, and pharmacokinetics of fluconazole in children with neoplastic diseases. J. Pediatr. 120 987-993.
275. E. Leibovitz, A. Iuster-Reicher, M. Amitai and B. Mogilner (1992) Systemic candidal infections associated with use of peripheral venous catheters in neonates: A 9-year experience. Clin. Infect. Dis. 14 485-491.
276. E. Leibovitz, M. Rigaud, S. Chandwani, et al. (1991) Disseminated fungal infection in children with human immunodeficiency virus. Pediatr. Infect. Dis. J. 10 888-894.
277. R.E. Lewis, M.E. Klepser and M.A. Pfaller (2000) In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. Diagn. Microbiol. Infect. Dis. 36 101-105.
278. C. Lin and S. Symchowicz (1975) Absorption, distribution, metabolism, and excretion of griseofulvin in man and animals. Drug Metab. Rev. 4 75-95.
279. C. Lin, J. Magat, R. Chang, et al. (1973) Absorption, metabolism and excretion of 14C-griseofulvin in man. J. Pharmacol. Exp. Ther. 187 415-422.
280. Linder, N., Shalit, I., Tallen-Gozani, E., et al.: Amphotericin B colloidal dispersion use in very low birth weight infants. Abstract 2438. In Abstracts of the 2000 Pediatric Academic Societies and American Academy of Pediatrics Joint Meeting, Chicago, 2000.
281. J. Lipozencic, M. Skerlev, R. Orofino-Costa, et al. (2002) A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species: Tinea Capitis Study Group. Br. J. Dermatol. 146 816-823.
282. A.C.Y. Lo, S.L. Lui, W.K. Lo, et al. (1997) The interaction of terbinafine and cyclosporine A in renal transplant patients. Br. J. Clin. Pharmacol. 43 340-341.
283. C.F. Lopez (1981) Recent developments in the therapy for chromoblastomycosis. Bull. Pan Am. Health. Org. 15 58-64.
284. O. Lortholary and B. Dupont (1997) Antifungal prophylaxis during neutropenia and immunodeficiency. Clin. Microbiol. Rev. 10 477-504.
285. A. Louie, M. Deziel, W. Liu, et al. (2005) Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. 49 5058-5068.
286. A. Louie, G.L. Drusano, P. Banerjee, et al. (1998) Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42 1105-1109.
287. S. Madani, D. Barilla, J. Cramer, et al. (2002) Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J. Clin. Pharmacol. 42 1211-1218.
288. J. Maertens, K. Lagrou, H. Deweerdt, et al. (2000) Disseminated infection by Scedosporium prolificans: An emerging fatality among haematology patients. Case report and review. Ann. Hematol. 79 340-344.
289. Maertens, J., Madero-Lopez, L., Reilly, A., et al.: A randomized, double-blind, multicenter trial of caspofungin versus liposomal amphotericin B for empirical antifungal therapy of pediatric patients with persistent fever and neutropenia. Abstracts of the 47 th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, 2007: Abstr. M-621, p. 435.
290. J. Maertens, I. Raad, G. Petrikkos, et al. (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39 1563-1571.
291. S.S. Magill, C. Shields, C.L. Sears, et al. (2006) Triazole cross-resistance among Candida spp.: Case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. 44 529-535.
292. M.C. Malet-Martino, R. Martino, M. deForni, et al. (1991) Flucytosine conversion to fluorouracil in humans: Does a correlation with gut flora status exist? A report of two cases using fluorine-19 magnetic resonance spectroscopy. Infection 19 178-180.
293. E.K. Manavathu, J.L. Cutright and P.H. Chandrasekar (1998) Organism-dependent fungicidal activities of azoles. Antimicrob. Agents Chemother. 42 3018-3021.
294. E.K. Manavathu, J.L. Cutright, D. Loebenberg and P.H. Chandrasekar (2000) A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J. Antimicrob. Chemother. 46 229-234.
295. E.K. Manavathu, M.S. Ramesh, I. Baskaran, et al. (2004) A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J. Antimicrob. Chemother. 53 386-389.
296. P. Manzoni, R. Arisio, M. Mostert, et al. (2006) Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: A single-center, 6-year, retrospective cohort study. Pediatrics 117 e22-e32.
297. P. Marchisio and N. Principi (1994) Treatment of oropharyngeal candidiasis in HIV-infected children with oral fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 13 338-340.
298. F. Marco, M.A. Pfaller, S.A. Messer and R.N. Jones (1998) Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med. Mycol. 36 433-436.
299. N.M. Marina, P.M. Flynn, G.K. Rivera and W.T. Hughes (1991) Candida tropicalis and Candida albicans fungemia in children with leukemia. Cancer 68 594-599.
300. K.A. Marr, F. Crippa, W. Leisenring, et al. (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103 1527-1533.
301. K.A. Marr, R. Hachem, G. Papanicolaou, et al. (2004) Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl. Infect. Dis. 6 110-116.
302. K.A. Marr, K. Seidel, M.A. Slavin, et al. (2000) Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood 96 2055-2061.
303. K.A. Marr, K. Seidel, T.C. White and R.A. Bowden (2000) Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181 309-316.
304. G. Medoff and G.S. Kobayashi (1980) Strategies in the treatment of systemic fungal infections. N. Engl. J. Med. 302 1451-1455.
305. G. Medoff, M. Comfort and G.S. Kobayashi (1971) Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc. Soc. Exp. Biol. Med. 138 571-574.
306. P. Mehta, A. Vinks, A. Filipovich, et al. (2006) High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: A pharmacokinetic study. Biol. Blood Marrow Transplant. 12 235-240.
307. J. Meletiadis, J.W. Mouton, J.F. Meis and P.E. Verweij (2003) In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 47 106-117.
308. J. Meletiadis, J.W. Mouton, J.L. Rodriguez-Tudela, et al. (2000) In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob. Agents Chemother. 44 470-472.
309. F. Menichetti, A. Del Favero, P. Martino, et al. (1999) Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell'. Adulto. Clin. Infect. Dis. 28 250-255.
310. F. Meunier, H.G. Prentice and O. Ringden (1991) Liposomal amphotericin B (AmBisome): Safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28(Suppl. B), 83-91.
311. C. Michel, L. Courdavault, R. al Khayat, et al. (1994) Fungal peritonitis in patients on peritoneal dialysis. Am. J. Nephrol. 14 113-120.
312. Y. Mikami, G.M. Scalarone, N. Kurita, et al. (1992) Synergistic postantifungal effect of flucytosine and fluconazole on Candida albicans. J. Med. Vet. Mycol. 30 197-206.
313. F. Minguez, M.L. Chiu, J.E. Lima, et al. (1994) Activity of fluconazole: Postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. J. Antimicrob. Chemother. 34 93-100.
314. A.S. Mitchell and J.T. Holland (1989) Fluconazole and phenytoin: A predictable inter-action. BMJ 298 1315.
315. J.F. Mohr, K.W. Finkel, J.H. Rex, et al. (2004) Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob. Agents Chemother. 48 3151-3153.
316. J.F. Mohr, A.C. Hall, C.D. Ericsson and L. Ostrosky-Zeichner (2005) Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation. Pharmacotherapy 25 426-428.
317. J.Z. Montgomerie, J.E. Edwards Jr. and L.B. Guze (1975) Synergism of amphotericin B and 5-fluorocytosine for Candida species. J. Infect. Dis. 132 82-86.
318. J. Mora-Duarte, R. Betts, C. Rotstein, et al. (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347 2020-2029.
319. P.L. Morselli (1989) Clinical pharmacology of the perinatal period and early infancy. Clin. Pharmacokinet. 17(Suppl. 1), 13-28.
320. J. Mosquera and D.W. Denning (2002) Azole cross-resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 46 556-557.
321. J. Mosquera, A. Sharp, C.B. Moore, et al. (2002) In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J. Antimicrob. Chemother. 50 189-194.
322. S.H. Mott, R.J. Packer, L.G. Vezina, et al. (1995) Encephalopathy with parkinsonian features in children following bone marrow transplantation and high dose amphotericin B. Ann. Neurol. 37 810-814.
323. F.M. Mueller, M. Weig, J. Peter and T.J. Walsh (2000) Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J. Antimicrob. Chemother. 46 338-340.
324. E. Muhl, T. Martens, H. Iven, et al. (2000) Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J. Clin. Pharmacol. 56 671-678.
325. Mycamine (micafungin sodium) for Injection Label Information (June 2006). Washington, D.C., U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
326. M.C. Nahata, K.B. Tallian and R.W. Force (1999) Pharmacokinetics of fluconazole in young infants. Eur. J. Drug Metab. Pharmacokinet. 24 155-157.
327. P.K. Narang, C.B. Trapnell, J.R. Schoenfelder, et al. (1994) Fluconazole and enhanced effect of rifabutin prophylaxis. N. Engl. J. Med. 330 1316-1317.
328. M.S. Naranjo, M. Trujillo, M.I. Munera, et al. (1990) Treatment of paracoccidioidomycosis with itraconazole. J. Med. Vet. Mycol. 28 67-76.
329. G. Natarajan, M. Lulic-Botica, C. Rongkavilit, et al. (2005) Experience with caspofungin in the treatment of persistent fungemia in neonates. J. Perinatol. 25 770-777.
330. C.E. Nath, P.J. Shaw, R. Gunning, et al. (1999) Amphotericin B in children with malignant disease: A comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrob. Agents Chemother. 43 1417-1423.
331. J.R. Nedelman, E. Gibiansky, B.A. Robbins, et al. (1996) Pharmacokinetics and pharmacodynamics of multiple-dose terbinafine. J. Clin. Pharmacol. 36 452-461.
332. M. Neely, H.S. Jafri, N. Seibel, et al. (2008) The pharmacokinetics and safety of caspofungin in older infants and toddlers Antimicrob Agents Chemother Dec 29 [Epub ahead of print].
333. R. Negroni, O. Palmieri, F. Koren, et al. (1987) Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans. Rev. Infect. Dis. 9(Suppl. 1), 47-50.
334. F. Nejjam, M. Zagula, M.D. Cabiac, et al. (1995) Pilot study of terbinafine in children suffering from tinea capitis: Evaluation of efficacy, safety and pharmacokinetics. Br. J. Dermatol. 132 98-105.
335. P.J. Neuvonen and K.M. Jalava (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 60 54-61.
336. M.H. Nguyen, F. Barchiesi, D.A. McGough, et al. (1995) In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob. Agents Chemother. 39 1691-1695.
337. D.P. Nicolau, H. Crowe, C.H. Nightingale and R. Quintiliani (1994) Effect of continuous arteriovenous hemofiltration on the pharmacokinetics of fluconazole. Pharmacotherapy 14 502-505.
338. J. Ninane, E. Gluckman, I. Hann, et al. (1994) A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Eur. J. Clin. Microbiol. Infect. Dis. 13 330-337.
339. V. Novelli and H. Holzel (1999) Safety and tolerability of fluconazole in children. Antimicrob. Agents Chemother. 43 1955-1960.
340. K.L. Oakley, C.B. Moore and D.W. Denning (1998) In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. 42 2726-2730.
341. C.M. Odio, R. Araya, L.E. Pinto, et al. (2004) Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J. 23 1093-1097.
342. Odio, C. M., Pinto, L. E., Alfaro, B., et al.: Pharmacokinetics (PK) of caspofungin (CAS) in six premature neonates (PNN) with invasive candidiasis (IC) at a neonatal intensive care unit (NNICU). Abstract LB-16. In Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2005.
343. K.T. Olkkola, J. Ahonen and P.J. Neuvonen (1996) The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg. 82 511-516.
344. Olson, J., Satorius, A., McAndrews, B., and Adler-Moore, J.: Treatment of systemic murine candidiasis with amphotericin B or different amphotericin B lipid formulations. Abstract B-11. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 1997, pp. 28.
345. M. Ortin, J.I. Olalla, M.J. Muruzabal, et al. (1999) Miconazole oral gel enhances acenocoumarol anticoagulant activity: A report of three cases. Ann. Pharmacother. 33 175-177.
346. M. Ortoneda, J. Capilla, F. Javier Pastor, et al. (2004) In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn. Microbiol. Infect. Dis. 48 69-71.
347. C.S. Osborne, I. Leitner, B. Hofbauer, et al. (2006) Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine. Antimicrob. Agents Chemother. 50 2234-2236.
348. C.L. Osowski, S.P. Dix, L.S. Lin, et al. (1996) Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 61 1268-1272.
349. D.P. O'Sullivan, C.A. Needham, A. Bangs, et al. (1996) Postmarketing surveillance of oral terbinafine in the UK: Report of a large cohort study. Br. J. Clin. Pharmacol. 42 559-565.
350. A.E. Oxford, H. Raistrick and P. Simonart (1939) Studies in the biochemistry of microorganisms: Griseofulvin, C17H17O6Cl, a metabolic product of Penicillium griseofulvum. Biochem. J. 33 240-248.
351. A.A. Panackal, J.L. Gribskov, J.F. Staab, et al. (2006) Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol. 44 1740-1743.
352. P.G. Pappas, R.W. Bradsher, S.W. Chapman, et al. (1995) Treatment of blastomycosis with fluconazole: A pilot study. Clin. Infect. Dis. 20 267-271.
353. P.G. Pappas, R.W. Bradsher, C.A. Kauffman, et al. (1997) Treatment of blastomycosis with higher doses of fluconazole: The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis. 25 200-205.
354. P.G. Pappas, J.H. Rex, J.D. Sobel, et al. (2004) Guidelines for treatment of candidiasis: Infectious Diseases Society of America. Clin. Infect. Dis. 38 161-189.
355. S. Park, R. Kelly, J.N. Kahn, et al. (2005) Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49 3264-3273.
356. S. Pasic, L. Flannagan and A.J. Cant (1997) Liposomal amphotericin B (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency. Bone Marrow Transplant 19 1229-1232.
357. A.C. Pasqualotto, S.J. Howard, C.B. Moore and D.W. Denning (2007) Flucytosine therapeutic monitoring: 15 years experience from the UK. J. Antimicrob. Chemother. 59 791-793.
358. Pedicone, L., Ullmann, A. J., Graybill, J., et al.: Comparison of posaconazole adverse event profiles in healthy volunteers and patients with invasive fungal infections. Abstract P-1106. In Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2004.
359. R. Pelletier, J. Peter, C. Antin, et al. (2000) Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus–infected children: In vitro and clinical correlations. J. Clin. Microbiol. 38 1563-1568.
360. J.R. Perfect, K.A. Marr, T.J. Walsh, et al. (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36 1122-1131.
361. V. Petraitis, R. Petraitiene, A.H. Groll, et al. (2002) Comparative antifungal activity of the echinocandin Micafungin against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 46 1857-1869.
362. K. Pettengell, J. Mynhardt, T. Kluyts, et al. (2004) Successful treatment of oesophageal candidiasis by micafungin: A novel systemic antifungal agent. FK463 South African Study Group. Aliment. Pharmacol. Ther. 20 475-481.
363. M.A. Pfaller, D.J. Diekema and D.J. Sheehan (2006) Interpretive breakpoints for fluconazole and Candida revisited: A blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 19 435-447.
364. M.A. Pfaller, S.A. Messer, L. Boyken, et al. (2002) In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: Global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob. Agents Chemother. 46 3518-3521.
365. M.A. Pfaller, S.A. Messer, L. Boyken, et al. (2004) Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J. Clin. Microbiol. 42 3137-3141.
366. M.A. Pfaller, S.A. Messer and S. Coffman (1997) In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. 41 763-766.
367. P. Phillips, S. Shafran, G. Garber, et al. (1997) Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients: Canadian Candidemia Study Group. Eur. J. Clin. Microbiol. Infect. Dis. 16 337-345.
368. P. Pitisuttithum, R. Negroni, J.R. Graybill, et al. (2005) Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. 56 745-755.
369. S.C. Piscitelli and K.D. Gallicano (2001) Interactions among drugs for HIV and opportunistic infections. N. Engl. J. Med. 344 984-996.
370. P.A. Pizzo, K.J. Robichaud, F.A. Gill, et al. (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am. J. Med. 72 101-111.
371. A. Polak (1990) Mode of action studies. J.F. Ryley (Eds) Handbook of Experimental Pharmacology 96 Berlin: Springer-Verlag 153-182.
372. W.G. Powderly, D. Finkelstein, J. Feinberg, et al. (1995) A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with AIDS. N. Engl. J. Med. 332 700-705.
373. A.G. Prentice, D.W. Warnock, S.A. Johnson, et al. (1995) Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J. Antimicrob. Chemother. 36 657-663.
374. H.G. Prentice, I.M. Hann, R. Herbrecht, et al. (1997) A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 98 711-718.
375. L. Purkins, N. Wood, P. Ghahramani, et al. (2002) Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46 2546-2553.
376. F. Queiroz-Telles, E. Berezin, G. Leverger, et al. (2008) Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: Substudy of a randomized double-blind trial. Pediatr. Infect. Dis. J. 27 820-826.
377. I. Raad, S. Chapman, R. Bradsher, et al. (2004) Posaconazole salvage therapy for invasive fungal infections. Abstract M-669. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, D.C.: American Society for Microbiology
378. I. Raad, J.R. Graybill, A.B. Bustamante, et al. (2006) Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin. Infect. Dis. 42 1726-1734.
379. E. Rallis and E. Frangoulis (2005) Successful treatment of subcutaneous phaeohyphomycosis owing to Exophiala jeanselmei with oral terbinafine. Int. J. Dermatol. 45 1369-1370.
380. E.D. Ralph, A.M. Khazindar, K.R. Barber and C.W.M. Grant (1991) Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob. Agents Chemother. 35 188-191.
381. A. Reboli, C. Rotstein, P. Pappas, et al. (2005) Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis (C/IC). Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, D.C.: American Society for Microbiology
382. S. Redding, J. Smith, G. Farinacci, et al. (1994) Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis. Clin. Infect. Dis. 18 240-242.
383. Rennie, R., Sand, C., and Sherburne, R.: Electron microscopic evidence of the effect of LY303366 on Aspergillus fumigatus. Abstract p451. In Abstracts of the 13th Meeting of the International Society for Human and Animal Mycology, Parma, Italy, 1997, pp. 191.
384. A. Restrepo, J. Robledo, I. Gomez, et al. (1986) Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch. Dermatol. 122 413-417.
385. A. Reuben, E. Anaissie, P.E. Nelson, et al. (1989) Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob. Agents Chemother. 33 1647-1649.
386. J.H. Rex, J.E. Bennett, A.M. Sugar, et al. (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331 1325-1330.
387. J.H. Rex, M.A. Pfaller, J.N. Galgiani, et al. (1997) Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro–in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin. Infect. Dis. 24 235-247.
388. J.H. Rex, M.G. Rinaldi and M.A. Pfaller (1995) Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39 1-8.
389. J. Reynes, C. Bazin, F. Ajana, et al. (1997) Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus–infected adults with oral candidiasis. Antimicrob. Agents Chemother. 41 2554-2558.
390. E.S. Reynolds, Z.M. Tomkiewicz and G.J. Dammin (1993) The renal lesion related to amphotericin B treatment for coccidioidomycosis. Med. Clin. North Am. 47 1149-1154.
391. O. Ringden (1993) Clinical use of AmBisome with special emphasis on experience in children. Bone Marrow Transplant 12(Suppl. 4), 149-150.
392. O. Ringden, F. Meunier, J. Tollemar, et al. (1991) Efficacy of amphotericin B encapsulated in liposome (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob Chemother. 28(Suppl. B), 73-82.
393. B. Robbins, C.T. Chang, J.A. Cramer, et al. (1996) Safe coadministration of terbinafine and terfenadine: A placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Clin. Pharmacol. Ther. 59 275-283.
394. M.M. Roden, L.D. Nelson, T.A. Knudsen, et al. (2003) Triad of acute infusion-related reactions associated with liposomal amphotericin B: Analysis of clinical and epidemiological characteristics. Clin. Infect. Dis. 36 1213-1220.
395. T.E. Rogers and J.N. Galgiani (1986) Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob. Agents Chemother. 30 418-422.
396. C. Rotstein, E.J. Bow, M. Laverdiere, et al. (1999) Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin. Infect. Dis. 28 331-340.
397. M. Rowland, S. Riegelman and W.L. Epstein (1968) Absorption kinetics of griseofulvin in man. J. Pharm. Sci. 57 984-989.
398. M. Ruhnke, A. Eigler, I. Tennagen, et al. (1994) Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J. Clin. Microbiol. 32 2092-2098.
399. Ruhnke, M., Kuse, E., Chetchotisad, H., et al.: Comparison of Micafungin and liposomal amphotericin B for invasive candidiasis. Abstract M-722c. In Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2005.
400. M. Ruhnke, R.A. Yeates, G. Pfaff, et al. (1995) Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. J. Antimicrob. Chemother. 35 641-647.
401. N.S. Ryder (1999) Activity of terbinafine against serious fungal pathogens. Mycoses 42(Suppl. 2), 115-119.
402. N.S. Ryder and I. Leitner (2001) Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med. Mycol. 39 91-95.
403. J.F. Ryley and S. McGregor (1988) A multiinfection model for antifungal screening in vivo. J. Antimicrob. Chemother. 22 353-358.
404. M.S. Saag, G.A. Cloud, J.R. Graybill, et al. (1999) A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis: National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin. Infect. Dis. 28 291-296.
405. M.S. Saag, W.J. Fessel, C.A. Kaufman, et al. (1999) Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res. Hum. Retroviruses 15 1413-1417.
406. T.I. Saari, K. Laine, K. Leino, et al. (2006) Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin. Pharmacol. Ther. 80 502-508.
407. F. Sabatelli, R. Patel, P.A. Mann, et al. (2006) In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50 2009-2015.
408. M.K. Sachs, L.M. Blanchard and P.J. Green (1993) Interaction of itraconazole and digoxin. Clin. Infect. Dis. 16 400-403.
409. Sáez-Llorens, X., Macias, M., Maiya, P., et al.: Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob. Agents Chemother. 2008 Dec 15. [Epub ahead of print].
410. J. Sahai, K. Gallicano, A. Pakuts and D.W. Cameron (1994) Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J. Infect. Dis. 169 1103-1107.
411. A. Saitoh, J. Homans and A. Kovacs (2000) Fluconazole treatment of coccidioidal meningitis in children: Two case reports and a review of the literature. Pediatr. Infect. Dis. J. 19 1204-1208.
412. E.S. Sandler, M.M. Mustafa, I. Tkaczewski, et al. (2000) Use of amphotericin B colloidal dispersion in children. J. Pediatr. Hematol. Oncol. 22 242-246.
413. D. Sanglard and F.C. Odds (2002) Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2 73-85.
414. Sansone, A., Courtney, R., and Krishna, G.: Evaluation of the drug interaction potential of posaconazole: Summary of 7 clinical pharmacology studies. Abstract P-1107. In Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2003.
415. A. Sansone, R. Courtney and L. Mellars (2004) Posaconazole has no clinically significant effect on QTc interval in healthy volunteers. Abstract A-1100. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, D.C.: American Society for Microbiology
416. A. Sansone-Parsons, G. Krishna, J. Simon, et al. (2007) Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 51 495-502.
417. B.P. Sawaya, J.P. Briggs and J. Schnermann (1995) Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties. J. Am. Soc. Nephrol. 6 154-164.
418. H. Saxen, K. Hoppu and M. Pohjavuori (1993) Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin. Pharmacol. Ther. 54 269-277.
419. G.M. Scalarone, Y. Mikami, N. Kurita, et al. (1992) Comparative studies on the postantifungal effect produced by the synergistic interaction of flucytosine and amphotericin B on Candida albicans. Mycopathologia 120 133-138.
420. G.M. Scalarone, Y. Mikami, N. Kurita, et al. (1992) The postantifungal effect of 5-fluorocytosine on Candida albicans. J. Antimicrob. Chemother. 29 129-136.
421. C. Schmitt, Y. Perel, J. Harousseau, et al. (2001) Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis. Antimicrob. Agents Chemother. 45 1561-1564.
422. H.J. Schmitt, J. Andrade, F. Edwards, et al. (1990) Inactivity of terbinafine in a rat model of pulmonary aspergillosis. Eur. J. Clin. Microbiol. Infect. Dis. 9 832-835.
423. H.J. Schmitt, E.M. Bernard, J. Andrade, et al. (1988) MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 32 780-781.
424. J. Scholz, M. Schulz, M. Steinfath, et al. (1995) Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient. J. Mol. Med. 73 145-147.
425. E.L. Schwartz, S. Hallam, R.E. Gallagher and P.H. Wiernik (1995) Inhibition of all- trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Biochem. Pharmacol. 50 923-928.
426. S. Schwartz, G. Behre, V. Heinemann, et al. (1999) Amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial. Blood 93 3654-3661.
427. S. Schwartz, M. Ruhnke, P. Ribaud, et al. (2005) Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106 2641-2645.
428. P. Schwarz, F. Dromer, O. Lortholary and E. Dannaoui (2003) In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob. Agents Chemother. 47 3361-3364.
429. R.E. Seay, T.A. Larson, J.P. Toscano, et al. (1995) Pharmacokinetics of fluconazole in immunocompromised children with leukemia or other hematologic diseases. Pharmacotherapy 15 52-58.
430. Seibel, N., and Walsh, T. J.: Safety, tolerance and pharmacokinetics of liposomal amphotericin B in children and adolescents. 1999.
431. N.L. Seibel, C. Schwartz, A. Arrieta, et al. (2005) Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 49 3317-3324.
432. S. Shadomy, A. Espinel-Ingroff and R.J. Gebhart (1985) In-vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia 23 125-132.
433. V.P. Shah, S. Riegelman and W.L. Epstein (1972) Determination of griseofulvin in skin, plasma, and sweat. J. Pharm. Sci. 61 634-636.
434. P.A. Sharkey, J.R. Graybill, M.G. Rinaldi, et al. (1990) Itraconazole treatment of phaeohyphomycosis. J. Am. Acad. Dermatol. 23 577-586.
435. H. Silm and M. Karelson (2002) Terbinafine: Efficacy and tolerability in young children with tinea capitis due to Microsporum canis. J. Eur. Acad. Dermatol. Venereol. 16 228-230.
436. A. Simon, M. Besuden, S. Vezmar, et al. (2007) Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Support. Care Cancer 15 213-220.
437. D.J. Skiest, J.A. Vazquez, G.M. Anstead, et al. (2007) Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin. Infect. Dis. 44 607-614.
438. M.A. Slavin, B. Osborne, R. Adams, et al. (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: A prospective, randomized, double-blind study. J. Infect. Dis. 171 1545-1552.
439. J.D. Sobel, S. Faro, R.W. Force, et al. (1998) Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am. J. Obstet. Gynecol. 178 203-211.
440. P.G. Sohnle, B.L. Hahn and M.D. Erdmann (1996) Effect of fluconazole on viability of Candida albicans over extended periods of time. Antimicrob. Agents Chemother. 40 2622-2625.
441. M. Soltani, C.M. Tobin, K.E. Bowker, et al. (2006) Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: A 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int. J. Antimicrob. Agents. 28 574-577.
442. Sorensen, K., Corcoran, E., Chen, S., et al.: Pharmacodynamic assessment of efflux- and target based resistance to fluconazole on efficacy against C. albicans in a mouse kidney infection model. Abstract 1271. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 1999, pp. 328.
443. J.R. Starke, O. Mason, W.G. Kramer, et al. (1987) Pharmacokinetics of amphotericin B in infants and children. J. Infect. Dis. 155 766-774.
444. G.E. Stein and N. Mummaw (1993) Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob. Agents Chemother. 37 89-92.
445. D.A. Stevens and J.Y. Lee (1997) Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch. Intern. Med. 157 1857-1862.
446. Stone, J. A., McCrea, J., Wickersham, P., et al.: A phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen. Abstract 854. In Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2000, pp. 26.
447. Suleiman, J., della Negra, M., and Llanos-Cuentas, A.: Open label study of micafungin in the treatment of esophageal candidiasis. Abstract M-722c. In Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2002.
448. D.A. Sutton, S.E. Sanche, S.G. Revankar, et al. (1999) In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J. Clin. Microbiol. 37 2343-2345.
449. Tang, T. R., Parr, R., Turner, W., et al.: LY-303366: A non-competitive inhibitor of (1,3)-b- d-glucan synthases from Candida albicans and Aspergillus fumigatus. Abstract 367. In Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 1993.
450. D.T. Te Dorsthorst, J.W. Mouton, C.J. van den Beukel, et al. (2004) Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates. Antimicrob. Agents Chemother. 48 3147-3150.
451. D.T. Te Dorsthorst, P.E. Verweij, J.F. Meis, et al. (2004) In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob. Agents Chemother. 48 2007-2013.
452. D.T. Te Dorsthorst, P.E. Verweij, J.F. Meis and J.W. Mouton (2005) Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 49 4220-4226.
453. M.L. Teitelbaum and V.E. Pearson (2001) Imipramine toxicity and terbinafine. Am. J. Psychiatry 158 2086.
454. M. Thaler, B. Pastakia, T.H. Shawker, et al. (1988) Hepatic candidiasis in cancer patients: The evolving picture of the syndrome. Ann. Intern. Med. 108 88-100.
455. J.R. Thompson, C.M. Douglas, W. Li, et al. (1999) A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. J. Bacteriol. 181 444-453.
456. A.M. Tobon, L. Franco, D. Espinal, et al. (1996) Disseminated histoplasmosis in children: The role of itraconazole therapy. Pediatr. Infect. Dis. J. 15 1002-1008.
457. S. Toon, C.E. Ross, R. Gokal and M. Rowland (1990) An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br. J. Clin. Pharmacol. 29 221-226.
458. H.A. Torres, R.Y. Hachem, R.F. Chemaly, et al. (2005) Posaconazole: A broad-spectrum triazole antifungal. Lancet Infect. Dis. 5 775-785.
459. L.B. Travis, G.D. Roberts and W.R. Wilson (1985) Clinical significance of Pseudallescheria boydii: A review of 10 years' experience. Mayo Clin. Proc. 60 531-537.
460. R. Trenschel, M. Ditschkowski, A.H. Elmaagacli, et al. (2005) Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant 35 583-586.
461. E.F. Trepanier, A.N. Nafziger and G.W. Amsden (1998) Effect of terbinafine on theophylline pharmacokinetics in healthy volunteers. Antimicrob. Agents Chemother. 42 695-697.
462. L. Trilles, B. Fernandez-Torres, S. Lazera Mdos, et al. (2004) In vitro antifungal susceptibility of Cryptococcus gattii. J. Clin. Microbiol. 42 4815-4817.
463. R.M. Tucker, D.W. Denning, E.G. Arathoon, et al. (1990) Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observations. J. Am. Acad. Dermatol. 23 593-601.
464. R.M. Tucker, D.W. Denning, B. Dupont and D.A. Stevens (1990) Itraconazole therapy for chronic coccidioidal meningitis. Ann. Intern. Med. 112 108-112.
465. R.M. Tucker, D.W. Denning, L.H. Hanson, et al. (1992) Interaction of azoles with rifampin, phenytoin, and carbamazepine: In vitro and clinical observations. Clin. Infect. Dis. 14 165-174.
466. R.M. Tucker, Y. Haq, D.W. Denning and D.A. Stevens (1990) Adverse events associated with itraconazole in 189 patients on chronic therapy. J. Antimicrob. Chemother. 26 561-566.
467. J.D. Turnidge, S. Gudmundsson, B. Vogelman and W.A. Craig (1994) The postantibiotic effect of antifungal agents against common pathogenic yeasts. J. Antimicrob. Chemother. 34 83-92.
468. S. Uko, L.M. Soghier, M. Vega, et al. (2006) Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 117 1243-1252.
469. A.J. Ullmann, J.H. Lipton, D.H. Vesole, et al. (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356 335-347.
470. O. Uzun and E.J. Anaissie (1995) Antifungal prophylaxis in patients with hematologic malignancies: A reappraisal. Blood 86 2063-2072.
471. J.A. van Burik, R.S. Hare, H.F. Solomon, et al. (2006) Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin. Infect. Dis. 42 e61-e65.
472. J.A. van Burik, V. Ratanatharathorn, D.E. Stepan, et al. (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39 1407-1416.
473. P. Van der Auwera, A.M. Ceuppens, C. Heymans and F. Meunier (1986) In vitro evaluation of various antifungal agents alone and in combination by using an automatic turbidimetric system combined with viable count determinations. Antimicrob. Agents Chemother. 29 997-1004.
474. C.M. van der Horst, M.S. Saag, G.A. Cloud, et al. (1997) Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 337 15-21.
475. P.H. van der Kuy and P.M. Hooymans (1998) Nortriptyline intoxication induced by terbinafine. BMJ 316 441.
476. H. Vanden Bossche and L. Koymans (1998) Cytochromes P450 in fungi. Mycoses 41(Suppl. 1), 32-38.
477. H. Vanden Bossche, F. Dromer, I. Improvisi, et al. (1998) Antifungal drug resistance in pathogenic fungi. Med. Mycol. 36(Suppl. 1), 119-128.
478. A. Varhe, K.T. Olkkola and P.J. Neuvonen (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 56 601-607.
479. J.A. Vasquez and J.D. Sobel (2006) Anidulafungin: A novel echinocandin. Clin. Infect. Dis. 43 215-222.
480. Vasquez, J. A., Northland, R., and Miller, S.: Posaconazole compared to fluconazole for oral candidiasis in HIV-positive patients. Abstract 1107. In Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2000.
481. J.A. Vasquez, D.J. Skiest, L. Nieto, et al. (2006) A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect. Dis. 42 1179-1186.
482. G.A. Vena, G. Micali, P. Santoianni, et al. (2005) Oral terbinafine in the treatment of multi-site seborrhoic dermatitis: A multicenter, double-blind placebo-controlled study. Int. J. Immunopathol. Pharmacol. 18 745-753.
483. A. Vermes, H.J. Guchelaar and J. Dankert (2000) Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46 171-179.
484. A. Vermes, H. van Der Sijs and H.J. Guchelaar (2000) Flucytosine: Correlation between toxicity and pharmacokinetic parameters. Chemotherapy 46 86-94.
485. A.E. Vickers, J.R. Sinclair, M. Zollinger, et al. (1999) Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab. Dispos. 27 1029-1038.
486. A. Villanueva, E.G. Arathoon, E. Gotuzzo, et al. (2001) A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33 1529-1535.
487. A. Villanueva, E. Gotuzzo, E.G. Arathoon, et al. (2002) A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113 294-299.
488. S. Wainer, P.A. Cooper, H. Gouws and A. Akierman (1997) Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr. Infect. Dis. J. 16 763-767.
489. T.J. Walsh, P.C. Adamson, N.L. Seibel, et al. (2005) Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49 4536-4545.
490. Walsh, T. J., Driscoll, T. A., Arietta, A. C., et al.: Pharmacokinetics, safety, and tolerability of voriconazole in hospitalized children. Abstract M-887. In Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 2006, pp. 45.
491. T.J. Walsh, R.W. Finberg, C. Arndt, et al. (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia: National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340 764-771.
492. T.J. Walsh, C. Gonzalez, C.A. Lyman, et al. (1996) Invasive fungal infections in children: Recent advances in diagnosis and treatment. Adv. Pediatr. Infect. Dis. 11 187-290.
493. T.J. Walsh, C.E. Gonzalez, S. Piscitelli, et al. (2000) Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J. Clin. Microbiol. 38 2369-2373.
494. T.J. Walsh, J.W. Hiemenz, N. Seibel, et al. (1998) Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 26 1383-1396.
495. T.J. Walsh, M.O. Karlsson, T. Driscoll, et al. (2004) Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48 2166-2172.
496. T.J. Walsh, I. Lutsar, T. Driscoll, et al. (2002) Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21 240-248.
497. T.J. Walsh, G. Melcher, M. Rinaldi, et al. (1990) Trichosporon beigelii: An emerging pathogen resistant to amphotericin B. J. Clin. Microbiol. 28 1616-1622.
498. T.J. Walsh, K.R. Newman, M. Moody, et al. (1986) Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) 65 268-279.
499. T.J. Walsh, P. Pappas, D.J. Winston, et al. (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346 225-234.
500. T.J. Walsh, J. Peter, D.A. McGough, et al. (1995) Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob. Agents Chemother. 39 1361-1364.
501. T.J. Walsh, I. Raad, T.F. Patterson, et al. (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin. Infect. Dis. 44 2-12.
502. T.J. Walsh, N.L. Seibel, C. Arndt, et al. (1999) Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr. Infect. Dis. J. 18 702-708.
503. T.J. Walsh, H. Teppler, G.R. Donowitz, et al. (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351 1391-1402.
504. T.J. Walsh, P. Whitcomb, S. Piscitelli, et al. (1997) Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob. Agents Chemother. 41 1944-1948.
505. P.D. Walzer and A. Ashbaugh (2002) Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 46 514-516.
506. D.W. Warnock, A. Turner and J. Burke (1986) Comparison of high performance liquid chromatography and microbiological methods for determination of itraconazole. J. Antimicrob. Chemother. 21 93-100.
507. J.A. Warwick and R.J. Corrall (1998) Serious interaction between warfarin and oral terbinafine. B. M. J. 316 440.
508. M. Weig and F.M. Muller (2001) Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus–infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 45 966-968.
509. D. Wexler, R. Courtney, W. Richards, et al. (2004) Effect of posaconazole on cytochrome P450 enzymes: A randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci. 21 645-653.
510. J. Wheat, R. Hafner, A.H. Korzun, et al. (1995) Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am. J. Med. 98 336-342.
511. J. Wheat, R. Hafner, M. Wulfsohn, et al. (1993) Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 118 610-616.
512. J. Wheat, S. McWhinney, R. Hafner, et al. (1997) Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome: National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am. J. Med. 103 223-232.
513. J. Wheat, G. Sarosi, D. McKinsey, et al. (2000) Practice guidelines for the management of patients with histoplasmosis: Infectious Diseases Society of America. Clin. Infect. Dis. 30 688-695.
514. M.H. White, E.J. Anaissie, S. Kusne, et al. (1997) Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin. Infect. Dis. 24 635-642.
515. M.H. White, R.A. Bowden, E.S. Sandler, et al. (1998) Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. 27 296-302.
516. T.C. White (1997) Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41 1482-1487.
517. N.P. Wiederhold, D.P. Kontoyiannis, J. Chi, et al. (2004) Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: Evidence of concentration-dependent activity. J. Infect. Dis. 190 1464-1471.
518. N.P. Wiederhold, V.H. Tam, J. Chi, et al. (2006) Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50 469-473.
519. J.M. Wiley, N.L. Seibel and T.J. Walsh (2005) Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr. Infect. Dis. J. 24 167-174.
520. J.R. Wingard (1994) Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin. Infect. Dis. 19(Suppl. 1), 49-53.
521. J.R. Wingard, P. Kubilis, L. Lee, et al. (1999) Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29 1402-1407.
522. J.R. Wingard, W.G. Merz, M.G. Rinaldi, et al. (1991) Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325 1274-1277.
523. J.R. Wingard, W.G. Merz, M.G. Rinaldi, et al. (1993) Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37 1847-1849.
524. D.J. Winston, R.T. Maziarz, P.H. Chandrasekar, et al. (2003) Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: A multicenter, randomized trial. Ann. Intern. Med. 138 705-713.
525. D.J. Winston, A. Pakrasi and R.W. Busuttil (1999) Prophylactic fluconazole in liver transplant recipients: A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 131 729-737.
526. A. Wong-Beringer, R.A. Jacobs and B.J. Guglielmo (1997) Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin. Infect. Dis. 27 603-618.
527. D.G. Wright, K.J. Robichaud, P.A. Pizzo and A.B. Deisseroth (1981) Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N. Engl. J. Med. 304 1185-1189.
528. G. Wurthwein, A.H. Groll, G. Hempel, et al. (2005) Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob. Agents Chemother. 49 5092-5098.
529. X. Xu, F. Deluna, J. Nishime, et al. (1997) Lack of metabolism-based drug interactions of MK-0991, a potent antifungal agent, in rats. Pharm. Res. 14(Suppl. 11), 558.
530. N. Yasui-Furukori, M. Saito, Y. Inoue, et al. (2007) Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur. J. Clin. Pharmacol. 63 51-56.
531. S.M. Yule, D. Walker, M. Cole, et al. (1999) The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab. Dispos. 27 417-421.
532. Zhanel, G. G., Saunders, D. G., Hoban, D. J., and Karlowsky, J. A.: Amphotericin B, azole, and 5-flucytosine pharmacodynamic parameters in the presence of human serum. Abstract 542. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C., American Society for Microbiology, 1999, pp. 23.
533. H. Zhou, M. Goldman, J. Wu, et al. (1998) A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J. Clin. Pharmacol. 38 593-602.